MCID: CYS014
MIFTS: 52

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 44 D003536
NCIt 50 C2971
SNOMED-CT 68 21008007
UMLS 73 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma is related to mucinous cystadenocarcinoma and ovarian cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and HIV Life Cycle. The drugs Fluorouracil and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and Increased cell death HMECs cells

Wikipedia : 76 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 308)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 33.8 KRT7 MUC1 MUC16 MUC2
2 ovarian cystadenocarcinoma 33.5 HRAS UBE4A ZNF217
3 bile duct cystadenocarcinoma 33.2 CEACAM5 KRT7 MUC1 MUC2
4 ovarian serous cystadenocarcinoma 31.9 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
5 serous cystadenocarcinoma 31.8 AKT1 ERBB2 FBXW7 HRAS MUC16 PGR
6 papillary serous adenocarcinoma 31.6 KRT7 PGR TP53
7 cystadenoma 31.1 KRT7 MUC1 MUC2 PGR
8 pseudomyxoma peritonei 30.6 KRT7 MUC1 MUC2 TP53
9 cystic teratoma 30.5 KRT7 MUC2 TP53
10 dermoid cyst 30.0 KRT7 MUC1 PGR
11 mucinous adenocarcinoma 30.0 KRT7 MUC1 MUC2
12 endosalpingiosis 29.9 KRT7 MUC1 PGR
13 adenocarcinoma 29.8 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
14 adenosquamous carcinoma 29.8 KRT7 MUC1 PIK3CA TP53
15 sclerosing hemangioma 29.8 KRT7 MUC1 PGR
16 appendix cancer 29.7 KRT7 MUC1 MUC2 TP53
17 intrahepatic cholangiocarcinoma 29.7 KRT7 MUC1 MUC2 TP53
18 transitional cell carcinoma 29.7 ERBB2 HRAS KRT7 TP53
19 mucinous ovarian cystadenoma 29.7 CEACAM5 KRT7 MUC1
20 carcinosarcoma 29.6 ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
21 polycystic liver disease 1 with or without kidney cysts 29.4 CEACAM3 CEACAM5 KRT7 MUC1 MUC16
22 squamous cell carcinoma 29.3 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
23 pancreatic ductal carcinoma 29.3 KRT7 MUC1 MUC2 TP53 VEGFA
24 papillary adenocarcinoma 29.1 CEACAM5 ERBB2 KRT7 MUC1 MUC16 MUC2
25 cholangiocarcinoma 29.0 AKT1 CEACAM3 CEACAM5 ERBB2 KRT7 MUC1
26 hepatocellular carcinoma 28.8 AKT1 CEACAM5 HRAS KRT7 PIK3CA TP53
27 ovarian cancer 1 28.7 AKT1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
28 ovarian cancer 28.6 AKT1 ERBB2 KRT7 MUC1 MUC16 MUC2
29 pancreatic cancer 28.3 AKT1 CEACAM3 CEACAM5 ERBB2 HRAS MUC1
30 papillary cystadenocarcinoma 12.4
31 ovarian mucinous cystadenocarcinoma 12.4
32 pancreatic serous cystadenocarcinoma 12.4
33 lung mucinous cystadenocarcinoma 12.2
34 ovarian clear cell cystadenocarcinoma 12.2
35 pancreatic cystadenocarcinoma 12.2
36 acinar cell cystadenocarcinoma 12.2
37 mucinous cystadenocarcinoma of the pancreas 12.2
38 appendix mucinous cystadenocarcinoma 12.0
39 breast mucinous cystadenocarcinoma 12.0
40 pancreatic non-invasive mucinous cystadenocarcinoma 12.0
41 pancreatic colloid cystadenocarcinoma 11.9
42 pancreatic invasive mucinous cystadenocarcinoma 11.9
43 multilocular clear cell renal cell carcinoma 11.2
44 appendix adenocarcinoma 11.1
45 multilocular cystic renal neoplasm of low malignant potential 11.0
46 gelatinous ascites 10.4
47 adult hepatocellular carcinoma 10.3 PIK3CA TP53
48 prostate adenoid cystic carcinoma 10.3 HRAS PIK3CA
49 spitz nevus 10.3 HRAS TP53
50 breast malignant phyllodes tumor 10.3 PGR TP53

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 ERBB2 HRAS MUC1 PPP2R1A VEGFA
2 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Cystadenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 AKT1 ERBB2 FBXW7 HRAS MUC2 PGR
2 cellular MP:0005384 10.07 AKT1 ERBB2 FBXW7 KRT7 MUC2 PGR
3 homeostasis/metabolism MP:0005376 10.03 AKT1 ERBB2 FBXW7 HRAS KRT7 MUC2
4 endocrine/exocrine gland MP:0005379 10.02 AKT1 ERBB2 FBXW7 HRAS MUC2 PGR
5 integument MP:0010771 9.76 AKT1 ERBB2 FBXW7 HRAS PGR PIK3CA
6 neoplasm MP:0002006 9.65 AKT1 ERBB2 FBXW7 HRAS MUC2 PGR
7 normal MP:0002873 9.23 AKT1 ERBB2 FBXW7 HRAS PGR PPP2R1A

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
6
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
11
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
15
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
17
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
19
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
20
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
21
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
22
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
23
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
24
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
25
Letrozole Approved, Investigational Phase 2, Phase 3,Phase 3 112809-51-5 3902
26
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
27
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
30
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
32
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
33
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
34
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
35
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
36 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 3
38 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
40 Alkylating Agents Phase 3,Phase 2,Phase 1
41 Calcium, Dietary Phase 3,Phase 2,Phase 1
42 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
46 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Mitomycins Phase 3
48 Folate Phase 3,Phase 2,Phase 1,Not Applicable
49 Antidotes Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 201)
# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
8 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
9 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
13 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
16 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
17 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
18 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
21 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
23 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
24 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
25 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
26 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
27 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
28 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
29 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
34 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
35 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
36 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
37 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
38 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
39 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
40 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
41 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
42 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
43 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
44 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
45 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
46 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
47 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
48 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
49 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
50 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

41
Ovary, Pancreas, Liver, Appendix, Breast, Salivary Gland, Lymph Node

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 789)
# Title Authors Year
1
Two protein-coding genes act as a novel clinical signature to predict prognosis in patients with ovarian serous cystadenocarcinoma. ( 29456732 )
2018
2
Mucinous Cystadenocarcinoma of the Breast: Report of 2 Cases Including One With Long-Term Local Recurrence. ( 29745281 )
2018
3
Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma. ( 29780137 )
2018
4
High-grade metastatic paratesticular cystadenocarcinoma. ( 29541584 )
2018
5
Mucinous cystadenocarcinoma arising from mucinous cystadenoma of the lung: case report and review of the literature. ( 29850162 )
2018
6
Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma (So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma"): Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change. ( 29016404 )
2018
7
Cystadenocarcinoma of the mandible. ( 29900928 )
2018
8
A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma. ( 30097905 )
2018
9
Gastric metastasis of ovarian serous cystadenocarcinoma. ( 30233254 )
2018
10
Bilateral Breast and Axillary Lymph Nodes Metastases of an Ovarian Serous Cystadenocarcinoma. ( 30287996 )
2018
11
Appendiceal mucinous cystadenocarcinoma with mural nodules of anaplastic carcinoma and K-RAS mutation. ( 30289401 )
2018
12
Hepatic Sclerosing Hemangioma with Predominance of the Sclerosed Area Mimicking a Biliary Cystadenocarcinoma. ( 30402303 )
2018
13
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. ( 30446011 )
2018
14
Biliary Cystadenoma and Cystadenocarcinoma of the Gallbladder: A Clinical Review. ( 28637540 )
2017
15
Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. ( 28551385 )
2017
16
Low-grade Cribriform Cystadenocarcinoma: A Review of the Literature and Case Report. ( 28507867 )
2017
17
Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. ( 27887203 )
2017
18
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
19
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )
2017
20
(18)F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )
2017
21
Acinar Cell Cystadenocarcinoma of the Pancreas. ( 29033770 )
2017
22
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
23
Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )
2017
24
The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )
2017
25
Papillary cystadenocarcinoma of the sublingual gland. ( 29124004 )
2017
26
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
27
Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )
2017
28
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 28976119 )
2017
29
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
30
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )
2017
31
Clinicopathological features and post-resection outcomes of biliary cystadenoma and cystadenocarcinoma of the liver. ( 28989996 )
2017
32
Biliary Cystadenoma and Cystadenocarcinoma of the Gallbladder: A Clinical Review. ( 30454154 )
2017
33
OK-432 injection therapy for cystadenocarcinoma of the parotid gland: A case report. ( 27140021 )
2016
34
Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade histopathologic malignancy. ( 27814773 )
2016
35
A Rare biliary cystic tumors: a case series of biliary cystadenomas and cystadenocarcinoma. ( 27049501 )
2016
36
Papillary Cystadenocarcinoma of the Parotid Gland: A Rare Case Report. ( 27504297 )
2016
37
Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )
2016
38
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )
2016
39
Vaginal fold prolapse in a dog with pyometra and ovarian papillary cystadenocarcinoma. ( 27003024 )
2016
40
Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms. ( 26875597 )
2016
41
Recto-vaginal septum cystadenocarcinoma: a case report and review of the literature. ( 27142415 )
2016
42
Cytomorphological features of papillary cystadenocarcinoma of parotid gland: A case report with review of literature. ( 27298629 )
2016
43
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
44
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
45
Clinicopathological characteristics, treatment, and survival outcomes of cystadenocarcinoma of the salivary gland: a population-based study. ( 27822061 )
2016
46
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
47
Cystic Epithelial Tumors of the Prostate: One Case Supporting a Continuous Spectrum From Cystadenoma to Cystadenocarcinoma With Ductal Features. ( 27631516 )
2016
48
Epididymal papillary cystadenocarcinoma metastasising to the testis in a patient with infertility managed with Onco-microTeSE. ( 27887012 )
2016
49
Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )
2016
50
Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ( 27367953 )
2016

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 AKT1 CEACAM3 ERBB2 FBXW7 HRAS MUC1
2
Show member pathways
13.74 AKT1 ERBB2 FBXW7 HRAS MUC1 MUC16
3
Show member pathways
13.48 AKT1 ERBB2 FBXW7 HRAS PIK3CA PPP2R1A
4
Show member pathways
13.36 AKT1 ERBB2 HRAS MUC1 PIK3CA PPP2R1A
5
Show member pathways
13.28 AKT1 CEACAM3 CEACAM5 HRAS PIK3CA PPP2R1A
6
Show member pathways
13.06 AKT1 HRAS PGR PIK3CA PPP2R1A VEGFA
7
Show member pathways
12.94 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
8
Show member pathways
12.92 AKT1 ERBB2 HRAS PIK3CA VEGFA
9
Show member pathways
12.92 AKT1 ERBB2 HRAS PIK3CA VEGFA
10
Show member pathways
12.9 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
11 12.85 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
12 12.79 AKT1 ERBB2 HRAS TP53 VEGFA
13
Show member pathways
12.75 AKT1 ERBB2 HRAS PIK3CA TP53
14
Show member pathways
12.74 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
15
Show member pathways
12.69 AKT1 ERBB2 HRAS PIK3CA PPP2R1A TP53
16
Show member pathways
12.62 AKT1 ERBB2 HRAS PIK3CA TP53
17
Show member pathways
12.58 AKT1 ERBB2 HRAS MUC2 PGR PIK3CA
18 12.56 ERBB2 HRAS PIK3CA TP53 VEGFA
19
Show member pathways
12.53 AKT1 ERBB2 HRAS PIK3CA TP53
20
Show member pathways
12.5 AKT1 ERBB2 HRAS PIK3CA
21
Show member pathways
12.46 HRAS MUC1 MUC16 MUC2
22 12.45 AKT1 HRAS PIK3CA TP53
23
Show member pathways
12.44 AKT1 HRAS PIK3CA PPP2R1A TP53
24
Show member pathways
12.44 AKT1 ERBB2 HRAS PIK3CA TP53
25
Show member pathways
12.44 AKT1 ERBB2 HRAS MUC1 PIK3CA TP53
26
Show member pathways
12.43 AKT1 HRAS PIK3CA VEGFA
27
Show member pathways
12.43 AKT1 HRAS PIK3CA VEGFA
28
Show member pathways
12.42 AKT1 HRAS PIK3CA TP53
29
Show member pathways
12.38 AKT1 PGR PIK3CA PPP2R1A
30
Show member pathways
12.36 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA
31
Show member pathways
12.35 AKT1 ERBB2 HRAS PIK3CA
32
Show member pathways
12.34 AKT1 HRAS PIK3CA TP53
33
Show member pathways
12.34 AKT1 ERBB2 HRAS PIK3CA
34
Show member pathways
12.29 AKT1 HRAS TP53 VEGFA
35
Show member pathways
12.27 CEACAM3 CEACAM5 HRAS PIK3CA
36
Show member pathways
12.22 AKT1 ERBB2 HRAS PIK3CA TP53
37 12.21 AKT1 HRAS PIK3CA TP53
38
Show member pathways
12.21 AKT1 HRAS PIK3CA TP53
39
Show member pathways
12.18 AKT1 ERBB2 HRAS PIK3CA
40
Show member pathways
12.17 AKT1 HRAS PIK3CA TP53
41
Show member pathways
12.15 AKT1 ERBB2 HRAS PIK3CA
42 12.13 AKT1 PIK3CA TP53 VEGFA
43
Show member pathways
12.07 AKT1 ERBB2 PIK3CA TP53
44 12.06 AKT1 ERBB2 HRAS PIK3CA TP53
45 12.02 AKT1 HRAS PIK3CA TP53
46 12.01 AKT1 MUC1 TP53 VEGFA
47
Show member pathways
11.97 ERBB2 HRAS PGR PIK3CA
48 11.97 AKT1 HRAS PIK3CA PPP2R1A TP53
49 11.94 AKT1 PIK3CA PPP2R1A
50 11.94 AKT1 ERBB2 HRAS PIK3CA TP53 VEGFA

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.44 AKT1 ERBB2 FBXW7 HRAS KRT7 MUC1
2 Golgi lumen GO:0005796 9.13 MUC1 MUC16 MUC2

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 AKT1 CEACAM5 ERBB2 TP53 VEGFA
2 positive regulation of gene expression GO:0010628 9.8 AKT1 ERBB2 HRAS TP53 VEGFA
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.69 AKT1 PIK3CA VEGFA
4 positive regulation of epithelial cell proliferation GO:0050679 9.65 ERBB2 HRAS VEGFA
5 positive regulation of MAP kinase activity GO:0043406 9.63 ERBB2 HRAS VEGFA
6 positive regulation of protein phosphorylation GO:0001934 9.62 AKT1 ERBB2 HRAS VEGFA
7 O-glycan processing GO:0016266 9.61 MUC1 MUC16 MUC2
8 negative regulation of macroautophagy GO:0016242 9.55 AKT1 PIK3CA
9 cytokine-mediated signaling pathway GO:0019221 9.55 AKT1 MUC1 PIK3CA TP53 VEGFA
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.52 MUC1 TP53
11 anoikis GO:0043276 9.49 AKT1 PIK3CA
12 phosphatidylinositol 3-kinase signaling GO:0014065 9.43 AKT1 ERBB2 PIK3CA
13 circadian behavior GO:0048512 9.37 TP53 USP2
14 negative regulation of gene expression GO:0010629 9.35 AKT1 FBXW7 HRAS PGR VEGFA
15 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 HRAS MUC1 MUC16 MUC2

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.86 AKT1 ERBB2 FBXW7 HRAS KRT7 MUC1
2 identical protein binding GO:0042802 9.23 AKT1 CEACAM5 ERBB2 FBXW7 PGR TP53

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....